Newave Pharmaceutical LLC has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
National Science & Technology Development Agency (NSTDA) has described cordycepin derivatives acting as viral replication inhibitors reported to be useful for the treatment of viral infections.
Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged prop-2-ynamide derivatives acting as EGFR (Exon 20 insertion [Ex20Ins] mutant) inhibitors reported to be useful for the treatment of cancer, in particular non-small-cell lung cancer (NSCLC).
Insilico Medicine Ltd. has identified postsynaptic density-95 (PSD-95) protein inhibitors acting as neuroprotective agents reported to be useful for the treatment of epilepsy, anxiety disorders, neurodegeneration, neuropathic pain, stroke and cerebral infarction.
Shanghai Helioson Pharmaceutical Co. Ltd. has synthesized molecular glue degraders comprising an E3 ubiquitin ligase coupled to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety acting as GSPT1 degradation inducers reported to be useful for the treatment of cancer.
NRG Therapeutics Ltd. has described mitochondrial permeability transition (MPT) inhibitors reported to be useful for the treatment of aging, ischemia-reperfusion injury, inflammation, neurodegeneration and autoimmune, metabolic and renal disorders.
Amenis Bioscience Inc. has identified anthranilic acid derivatives acting as peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) and viral replication inhibitors reported to be useful for the treatment of parasitic and viral infections, obesity, cancer, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), inflammatory bowel disease and pulmonary fibrosis.
Innovstone Therapeutics Ltd. has synthesized leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.
RSS